Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients.
Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients.
复制标题
DOI：
10.1016/j.trim.2022.101713
复制
发表时间：
2022-12
影响因子：
1.5
通讯作者：
Ishida, Fumihiro
中科院分区：
文献类型：
--
作者：
Nakazawa, Hideyuki;Sakai, Kaoko;Sudo, Yuriko;Iwabuchi, Ryohei;Sakai, Hitoshi;Nishina, Sayaka;Kawakami, Toru;Kawakami, Fumihiro;Matsuzawa, Shuji;Ito, Toshiro;Kitahara, Mari;Kamijo, Yuji;Umemura, Takeji;Ushiki, Atsuhito;Kanai, Shinichiro;Tsuchiya, Hiroyuki;Ishida, Fumihiro
针对SARS-COV-2的疫苗接种被认为是遏制这一流行病的最有希望的方法。免疫功能低下的患者，如血液恶性肿瘤患者和器官移植受者，被认为更容易感染，但这些高危患者在疫苗接种的早期临床试验中代表性不足。尽管越来越多的研究表明，与健康对照组相比，这些高危患者群体对COVID-19疫苗接种的体液反应可能不是最佳的，但这些群体之间进一步比较分析的临床和战略信息尚未得到充分描述。在总共187名接受同种异体造血移植、肾移植、抗CD 20抗体治疗或抗CD 38抗体治疗的患者和66名健康对照者中评价了两剂BNT 162 b2疫苗接种后的体液应答。与健康对照组相比，肾移植患者、抗CD 20抗体治疗患者和抗CD 38抗体治疗患者接种疫苗后1 - 3个月的早期应答显著较差。而异基因造血移植患者的早期体液免疫应答与健康对照组相当。在肾移植患者和抗CD 20治疗患者中，疫苗接种后6个月的晚期应答仍不理想。在我们的患者组中，肾移植受者在接种疫苗后的抗体滴度最低，无论何时接种疫苗。接受同种异体造血移植的患者获得了与对照组相当的血清学应答，特别是如果他们在移植后>300天接种疫苗，但是如果在移植后300天内接种疫苗，则应答是次优的。我们的研究结果可以为政策制定者提供关键信息，以进一步对高危人群进行分层，有助于更好地分配资源，包括额外的加强疫苗接种。肾移植患者的体液反应明显较差，而异基因干细胞移植患者在接种2剂BNT 162 b2疫苗后与健康对照组无显著差异。
Vaccination against SARS-COV-2 is considered the most promising approach to curbing the pandemic. Patients with an immunocompromised state, such as those with hematological malignancies and organ transplantation recipients, are considered more susceptible to infection, but these at-risk patients were underrepresented in early clinical trials for vaccination. Although a growing body of studies suggests that the humoral response to COVID-19 vaccination in each of these at-risk groups of patients may be suboptimal in comparison to healthy controls, a clinical and strategic information for the further comparative analysis among these groups is not fully described. The humoral responses after two doses of BNT162b2 vaccination were evaluated in a total of 187 patients either with allogeneic hematopoietic transplantation, with renal transplantation, with anti-CD20 antibody therapy, or with anti-CD38 antibody therapy, and in 66 healthy controls. The early response at one to three months after vaccination was significantly inferior among patients with renal transplantation, patients with anti-CD20 antibody therapy, and patients with anti-CD38 antibody therapy in comparison to healthy control. But the patients with allogeneic hematopoietic transplantation showed early humoral response comparable to healthy control. The late response at 6 months after vaccination was still suboptimal among patients with renal transplantation and patients with anti-CD20 therapy. Among our patient group, renal transplant recipients had the lowest antibody titers after vaccination regardless of timing of vaccination. Patients who had received allogeneic hematopoietic transplantation attained a comparable serological response to the control group especially if they are vaccinated >300 days after transplantation, but the response was suboptimal if the vaccination was within 300 days after transplantation. Our results may provide policy makers with critical information for the further stratification of at-risk groups, helping contribute to a better allocation of resources, including additional booster vaccination. A significantly inferior humoral response among patients with kidney transplantation was remarkable, while patients with allogeneic stem cell transplantation was not significantly different with healthy controls after 2 doses of BNT162b2 vaccine.
登录
查看更多内容
影响因子：
7.5
作者：
Jiménez M;Roldán E;Fernández-Naval C;Villacampa G;Martinez-Gallo M;Medina-Gil D;Peralta-Garzón S;Pujadas G;Hernández C;Pagès C;Gironella M;Fox L;Orti G;Barba P;Pumarola T;Cabirta A;Catalá E;Valentín M;Marín-Niebla A;Orfao A;González M;Campins M;Ruiz-Camps I;Valcárcel D;Bosch F;Hernández M;Crespo M;Esperalba J;Abrisqueta P
通讯作者：
Abrisqueta P
影响因子：
39
作者：
Reindl-Schwaighofer R;Heinzel A;Mayrdorfer M;Jabbour R;Hofbauer TM;Merrelaar A;Eder M;Regele F;Doberer K;Spechtl P;Aschauer C;Koblischke M;Paschen C;Eskandary F;Hu K;Öhler B;Bhandal A;Kleibenböck S;Jagoditsch RI;Reiskopf B;Heger F;Bond G;Böhmig GA;Strassl R;Weseslindtner L;Indra A;Aberle JH;Binder M;Oberbauer R
通讯作者：
Oberbauer R
影响因子：
6.5
作者：
Mori, Akio;Onozawa, Masahiro;Tsukamoto, Shihori;Ishio, Takashi;Yokoyama, Emi;Izumiyama, Koh;Saito, Makoto;Muraki, Haruna;Morioka, Masanobu;Teshima, Takanori;Kondo, Takeshi
通讯作者：
Kondo, Takeshi
影响因子：
3
作者：
Melin J;Svensson MK;Albinsson B;Winqvist O;Pauksens K
通讯作者：
Pauksens K
影响因子：
12.8
作者：
Malard F;Gaugler B;Gozlan J;Bouquet L;Fofana D;Siblany L;Eshagh D;Adotevi O;Laheurte C;Ricard L;Dulery R;Stocker N;van de Wyngaert Z;Genthon A;Banet A;Memoli M;Ikhlef S;Sestilli S;Vekhof A;Brissot E;Marjanovic Z;Chantran Y;Cuervo N;Ballot E;Morand-Joubert L;Mohty M
通讯作者：
Mohty M